Torrent Pharmaceuticals 获得了 Vonoprazan 在印度的非独家专利许可。 Torrent Pharmaceuticals secures non-exclusive patent licensing for Vonoprazan in India.

Torrent Pharmaceuticals Ltd. 与武田制药达成非独家专利许可协议，在印度商业化新型胃肠药物 Vonoprazan。 Torrent Pharmaceuticals Ltd. secured a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialize Vonoprazan, a novel gastrointestinal drug, in India. 该药物是一种钾竞争性酸阻滞剂，用于治疗影响印度 8.2% 人口的 GERD，市场价值为 8,064 亿印度卢比。 The drug, a potassium-competitive acid blocker, treats GERD affecting 8.2% of India's population, worth INR 8,064cr in the market. Torrent 将以 Kabvie 的名称销售该药物，提供新的治疗选择。 Torrent will market it as Kabvie, providing new treatment options.

文章

The Hindu Business Line

Financial Express

The Economic Times

-- 显示更少 --

延伸阅读

相关故事